Dr. Daniel A. Rakowski, MD
Nephrology (Kidney) (Nephrology Physician)
- Medicare participating
At a glance
- Medical school
- Hahnemann University College of Medicine (1999)
- Years since graduation
- 27
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 645
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1999Medical school: Hahnemann University College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nephrology Physician primary
VA license 010129882
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Sentara Leigh Hospital Norfolk, VA
- Sentara Princess Anne Hospital Virginia Beach, VA
- Sentara Obici Hospital Suffolk, VA
- Chesapeake General Hospital Chesapeake, VA
- The Outer Banks Hospital, Inc Nags Head, NC
Medical groups
- Tidewater Kidney Specialists Inc (23 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 645
- Services billed
- 2,175
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 724 | 249 |
| Established patient office or other outpatient visit, 30-39 minutes | 510 | 263 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 391 | 52 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 171 | 76 |
| Home dialysis services per month (20 years or older) | 159 | 37 |
| Dialysis services, per day, less than full month service (20 years or older) | 151 | 15 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 97 | 96 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 67 | 33 |
| Hemodialysis procedure with physician evaluation | 39 | 20 |
| New patient office or other outpatient visit, 45-59 minutes | 38 | 38 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 24 companies reported 63 payments worth $1,583 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $176 |
|---|---|
| Vantive US Healthcare LLC | $172 |
| Stryker Corporation | $155 |
| Novartis Pharmaceuticals Corporation | $102 |
| Travere Therapeutics, Inc. | $99.21 |
| Otsuka America Pharmaceutical, Inc. | $97.34 |
| Scpharmaceuticals Inc. | $93.72 |
| GlaxoSmithKline, LLC. | $92.42 |
| Food and Beverage | $1,579 |
|---|---|
| Education | $3.71 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Travere Therapeutics, Inc. Oct 21, 2025 | Education Filspari · Kidney Disease · in-kind | $1.66 |
| Travere Therapeutics, Inc. Oct 21, 2025 | Education Filspari · Kidney Disease · in-kind | $1.66 |
| Travere Therapeutics, Inc. Dec 4, 2025 | Education Filspari · Kidney Disease · in-kind | $0.39 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $209,709 in research payments for these studies, mostly to the institutions running them.
- Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
Csl Behring · Recruiting · NCT05485961 - A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis
Akebia Therapeutics Inc
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.